Selecting patients for phase 1 studies remains challenging. Given the lack of clear and reliable guidance for the estimation of life expectancy, we retrospectively assessed predictive factors of early death (within 90 days following inclusion) among these patients.
Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics.
